The ACE inhibitor alacepril suppresses atherogenesis independent of serum lipids in cholesterol-fed rabbits--critical analysis with new ultrasound technique.
The effects of alacepril, an angiotensin converting enzyme inhibitor, on atherogenesis were examined in rabbits fed a hypercholesterol diet. The process of atherogenesis was evaluated in vitro by high-resolution transesophageal ultrasonography (TEE phi 4 mm, 7.5 MHz), by direct histological examination and by serum lipid examination. Of the 38 subjects, 18 were designated as the control hypercholesterol group (CH) and 20 received oral alacepril at 90 mg/day (ACE) for 13-22 weeks. Three rabbits in each group died due to pneumonia. TEE enabled a clear diagnosis as either normal, early stage or late stage of atherosclerosis. The intimal-medial thickness was significantly less in the ACE group than in the CH group, but only over the middle portion of the aorta. The ACE group had a smaller area of atheromatous plaque than the CH group (atheromatous index: 37 +/- 20* and 60 +/- 30% respectively, *p < 0.02). Serum cholesterol and triglycerides were similar in the CH group (1590 +/- 653, 258 +/- 224) and the ACE group (1574 +/- 824, 303 +/- 360 respectively). In conclusion, alacepril reduced both the area of atheromatous atheroma plaque and wall hypertrophy independent of serum lipids in cholesterol-fed rabbits. In vitro miniature TEE is a dependable method for evaluating atherosclerosis in rabbits with hypercholesterolemia.